Ngl Fine-chem Ltd. · NSE:NGLFINE
Ngl Fine-chem — Q3 FY2024 Earnings Presentation
16 slides from Ngl Fine-chem's earnings presentation, Feb 16, 2024
Slide 1: Covering letter to stock exchanges
Regd. Office 301, E – Square, Subhash Road, Vile Parle East, Mumbai 400057 Maharashtra, India. Tel.: (+91 22) 40842222, Fax: (+91 22) 2610 8030, Email: info@nglfinechem.com CIN L24110MH1981PLC025884,Website www.nglfinechem.com February 16, 2024 To, Listing Department, Listing Department, The BSE Lim
Slide 2: NGL Fine-Chem Limited Investor Presentation Q3FY24
NGL Fine-Chem Limited INVESTOR PRESENTATION Q3FY24
Slide 3: Disclaimer
Disclaimer This investor presentation has been prepared by NGL Fine-Chem Limited and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof ) delivered or supplied should not be
Slide 4: Inside This Presentation
Inside Pg. No. Pg. No. This Presentation 04 08 Q3FY24 Over view, Highlights Key Strengths and Strategy Pg. No. 13 Historical Financial Performance
Slide 5: Q3FY24 Highlights
01 Q3FY24 Highlights 05 M A N A G E M E N T C O M M E N TA R Y 06 Q UA R T E R LY O P E R AT I O N A L M E T R I C S 07 S U M M A R Y O F F I N A N C I A L S TAT E M E N T S
Slide 6: Management Commentary
MANAGEMENT COMMENTARY Dear Shareholders, In light of the promising signs of demand recovery, we are accelerating our CAPEX plans, aiming to complete Reflecting on Q3FY24, I am pleased to share that NGL phase 1 by the end of Q2FY25. With an investment of Fine Chem Limited has maintained its trajector
Slide 7: Operational Metrics
Operational Metrics SEGMENTAL REVENUE MIX PRODUCT CONCENTRATION PARTICULARS Q3FY23 Q2FY24 Q3FY24 PARTICULARS Q3FY23 Q2FY24 Q3FY24 ANIMAL API 81% 83% 94% TOP 3 PRODUCTS 39% 29% 36% HUMAN API 5% 6% 2% TOP 5 PRODUCTS 51% 41% 51% INTERMEDIATES 8% 5% 2% TOP 10 PRODUCTS 76% 65% 72% FORMULATIONS 6% 6% 2% G
Slide 8: Summary of Profit and Loss Statement
Summary of Profit and Loss Statement ₹ IN CRORES PARTICUL ARS Q3FY23 Q2FY24 Q3FY24 Q-o-Q Y-o-Y 9MFY23 9MFY24 Y-o-Y REVENUE FROM OPERATIONS 71.93 80.18 87.95 9.70% 22.27% 200.26 239.23 19.46% OTHER INCOME 0.69 3.22 3.68 14.32% 434.64% 6.48 10.17 56.86% TOTAL INCOME 72.62 83.40 91.63 9.87% 26.17% 206.
Slide 9: Overview, Strengths and Strategy
02 Overview, Strengths and Strategy 09 L E A D I N G A N I M A L H E A LT H C O M PA N Y 10 LEADERSHIP IN VETERINARY API SEGMENT 11 S TAT E - O F - T H E - A R T M A N U FA C T U R I N G C A PA B I L I T I E S 12 S T R AT E G Y F O R N E X T L E G O F G R O W T H
Slide 10: Leading Animal Health Company
Leading Animal Health Company COMPREHENSIVE MARKET MANUFACTURING LARGE GLOBAL LONG STANDING PRODUCT LEADERSHIP EXCELLENCE PRESENCE CUSTOMER PORTFOLIO IN VETERINARY API RELATIONSHIPS • 26 APIs (24 Veterinary • Leadership in top • 3 state of the art • 45+ countries across • ~400 customers APIs, 2 Huma
Slide 11: Leadership in Veterinary API Segment
Leadership in Veterinary API Segment REVENUE FROM VETERINARY CUSTOMER & PRODUCT Strong controls of processes with 95% in-house manufacturing and API SEGMENT (₹ IN CRORES) 15% CAGR CONCENTRATION (OF SALES FY23) backward integrated facilities leading to cost competitiveness FY23 225 CUSTOMER PRODUCT F
Slide 12: State-of-the-art Manufacturing Capabilities
State-of-the-art Manufacturing Capabilities HIGHLIGHTS 3 manufacturing facilities located at Tarapur & Navi 10,000 m 2 102 m 3 194 m 3 AREA OF GLASS-LINED STAINLESS STEEL Mumbai, Maharashtra, MANUFACTURING REACTORS REACTORS designed to meet the FACILITIES requirements of regulatory agencies and are
Slide 13: Strategy for next leg of growth
Strategy for next leg of growth BROWNFIELD EXPANSION • Completed expansion in ONGOING INITIATIVES subsidiary Macrotech TO INCREASE • Additional capacities of a CAPACITIES TO MEET intermediates GROWING DEMAND • Commercial production started GREENFIELD EXPANSION AT TARAPUR • 50% capacity expansion wit
Slide 14: Historical Financial Performance
03 Historical Financial Performance 14 ROBUST FINANCIAL PERFORMANCE
Slide 15: Robust Financial Performance
Robust Financial Performance REVENUE EBITDA PAT (₹ IN CRORES) (₹ IN CRORES) (₹ IN CRORES) FY23 278 FY23 34 FY23 21 FY22 318 FY22 68 FY22 50 FY21 258 FY21 80 FY21 57 FY20 152 FY20 19 FY20 8 FY19 153 FY19 32 FY19 20 0 50 100 150 200 250 300 350 0 10 20 30 40 50 60 70 80 90 0 10 20 30 40 50 60 GROSS MA
Slide 16: Thank You
FOR ANY FURTHER INFORMATION, PLEASE CONTACT Thank You Pallavi Pednekar Abhishek Mehra NGL FINE-CHEM TIL ADVISORS PRIVATE LIMITED LIMITED cs@nglfinechem.com abhishek@theinvestmentlab.in +91 22 40842222 +91 95588 14500 Corporate Office 301, E-square, Subhash Road, Vile Parle (East), Mumbai - 400057, M